Kellie Vaughn
Psychiatric/Mental Health · Birmingham, ALNPI 1245705698
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,977 of the $11,643 with a category attached, or 68.5%. 22 manufacturers reported payments, led by AbbVie at 41.3% of the total. Reporting peaked in 2021 at $3,725 and has fallen 51.0% since, to $1,825 in 2025. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 417 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$742
- Takeda Pharmaceuticals U.S.A., Inc.$593
- Alkermes, Inc.$591
- Teva Pharmaceuticals USA, Inc.$364
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$3,57531%
- Travel & lodging$430%
- Food & beverage$7,97769%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $4,804 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 103 | $2,367 |
| Otsuka America Pharmaceutical, Inc. | 43 | $742 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $593 |
| Alkermes, Inc. | 27 | $591 |
| Teva Pharmaceuticals USA, Inc. | 22 | $364 |
| Johnson & Johnson | 17 | $363 |
| Supernus Pharmaceuticals, Inc. | 23 | $353 |
| Axsome Therapeutics, Inc. | 12 | $281 |
| Neurocrine Biosciences, Inc. | 10 | $201 |
| Vanda Pharmaceuticals Inc. | 8 | $189 |
| Corium, LLC | 9 | $173 |
| Lundbeck LLC | 6 | $141 |
| E.r. Squibb & Sons, L.L.C. | 5 | $113 |
| Tris Pharma Inc | 5 | $90 |
| Sunovion Pharmaceuticals Inc. | 4 | $90 |
| Ironshore Pharmaceuticals Inc. | 4 | $61 |
| Almatica Pharma LLC | 2 | $41 |
| Adlon Therapeutics L.p. | 2 | $30 |
| Neos Therapeutics, LP | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $19 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,643 in reported general payments places this provider in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 17 | $23,756 |
| CaplytaLumateperone Tosylate | 14 | $23,213 |
| Atomoxetine Hcl | 13 | $2,640 |
| Ziprasidone Hcl | 12 | $2,002 |
| Trazodone Hcl | 34 | $713 |
| Quetiapine Fumarate | 24 | $633 |
| Guanfacine Hcl ErGuanfacine Hcl | 13 | $499 |
| Duloxetine Hcl | 19 | $470 |
| Escitalopram Oxalate | 23 | $390 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $349 |
| Haloperidol | 25 | $346 |
| Risperidone | 13 | $322 |
| Benztropine Mesylate | 17 | $206 |
| Olanzapine | 18 | $142 |
| Sertraline Hcl | 12 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $4,804 | $23,75617 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,367 | $23,21314 claims |
| Almatica Pharma LLCSertraline Hcl | $41 | $13012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Birmingham
- Yuliya SpencerBirmingham$65K
- David CoffmanBirmingham$13K
- Tiffany WallerBirmingham$12K
- Amanda BoydBirmingham$10K
- Hannah KeslerBirmingham$9K
- Judy ClarkBirmingham$9K
- Jessica AdwellBirmingham$9K
- Pamela Kite TrullBirmingham$9K
- Lacey PodyBirmingham$7K
- Emily MartinBirmingham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.